Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress Topline data from multiple Phase 2 studies expected throughout 2025 Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, CA, May 8, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing inno ...